.png)
.png)
Cryoport Systems officially launches global supply chain hub in Stevenage, U.K.
NASHVILLE, Tenn. and STEVENAGE, United Kingdom,– Cryoport, Inc., a global leader in innovative supply chain solutions for the cell and gene therapy industry, is thrilled to announce the official launch of the Cryoport Systems state-of-the-art global supply chain hub in Stevenage, U.K. This new facility, operational since June 17, 2024, marks a significant milestone in Cryoport’s strategic expansion into Europe and reinforces its commitment to supporting the rapidly growing cell and gene therapy sector in the region.
Located within the renowned bioscience cluster at the Cell and Gene Therapy Catapult’s large-scale cell and gene therapy Stevenage Manufacturing Innovation Centre, Cryoport’s new hub offers advanced, end-to-end logistics and supply chain solutions. These solutions include Cryoport’s signature cryogenic shipping systems such as Cryoport Express® High Volume Shippers and Standard Volume Shippers, all equipped with Smartpak II® technology for enhanced risk mitigation and logistics support, as well as the Cryoshuttle® local pickup and delivery service for exceptional support of the first and last mile of the sensitive material supply chain.
“Establishing this Global Supply Chain Hub in Stevenage is a crucial step in our mission to provide seamless supply chain services to the cell and gene therapy community in the U.K.,” said Jerrell Shelton, CEO of Cryoport. “This facility will not only enhance our ability to support clinical development and commercialization efforts but also strengthen our global supply chain infrastructure, aligning with our broader growth strategy.”
The strategic collaboration with the Cell and Gene Therapy Catapult (CGT Catapult), announced in October 2023, underpins the establishment of this GMP-compliant supply chain hub. This partnership ensures that CGT Catapult collaborators and the broader U.K. cell and gene therapy ecosystem have direct access to Cryoport’s integrated supply chain and risk mitigation services, fostering innovation and accelerating therapeutic advancements.
In addition to the new Stevenage facility, Cryoport Systems has recently expanded its footprint in Pont-du-Chateau, France. This expansion, completed earlier this month, further solidifies end-to-end support in Europe, enhancing full-scope comprehensive supply chain solutions across the continent. The Pont-du-Chateau facility will work in tandem with the Stevenage Global Supply Chain Hub and our facility in Amsterdam, the Netherlands to support the growing demands of the cell and gene therapy industry.
To mark this significant milestone, Cryoport, in collaboration with CGT Catapult, will host a grand opening event in September 2024. This event will bring together key stakeholders, industry leaders, and collaborators to celebrate the launch and discuss the future of cell and gene therapy supply chain and logistics in Europe.
Cryoport’s expansion into Europe with this new Global Supply Chain Hub underscores the company’s dedication to Enabling the Outcome™ for patients worldwide. By providing advanced supply chain and logistics solutions, Cryoport is poised to support the life sciences community in overcoming supply chain challenges and driving the next generation of medical breakthroughs.
Located within the renowned bioscience cluster at the Cell and Gene Therapy Catapult’s large-scale cell and gene therapy Stevenage Manufacturing Innovation Centre, Cryoport’s new hub offers advanced, end-to-end logistics and supply chain solutions. These solutions include Cryoport’s signature cryogenic shipping systems such as Cryoport Express® High Volume Shippers and Standard Volume Shippers, all equipped with Smartpak II® technology for enhanced risk mitigation and logistics support, as well as the Cryoshuttle® local pickup and delivery service for exceptional support of the first and last mile of the sensitive material supply chain.
“Establishing this Global Supply Chain Hub in Stevenage is a crucial step in our mission to provide seamless supply chain services to the cell and gene therapy community in the U.K.,” said Jerrell Shelton, CEO of Cryoport. “This facility will not only enhance our ability to support clinical development and commercialization efforts but also strengthen our global supply chain infrastructure, aligning with our broader growth strategy.”
The strategic collaboration with the Cell and Gene Therapy Catapult (CGT Catapult), announced in October 2023, underpins the establishment of this GMP-compliant supply chain hub. This partnership ensures that CGT Catapult collaborators and the broader U.K. cell and gene therapy ecosystem have direct access to Cryoport’s integrated supply chain and risk mitigation services, fostering innovation and accelerating therapeutic advancements.
In addition to the new Stevenage facility, Cryoport Systems has recently expanded its footprint in Pont-du-Chateau, France. This expansion, completed earlier this month, further solidifies end-to-end support in Europe, enhancing full-scope comprehensive supply chain solutions across the continent. The Pont-du-Chateau facility will work in tandem with the Stevenage Global Supply Chain Hub and our facility in Amsterdam, the Netherlands to support the growing demands of the cell and gene therapy industry.
To mark this significant milestone, Cryoport, in collaboration with CGT Catapult, will host a grand opening event in September 2024. This event will bring together key stakeholders, industry leaders, and collaborators to celebrate the launch and discuss the future of cell and gene therapy supply chain and logistics in Europe.
Cryoport’s expansion into Europe with this new Global Supply Chain Hub underscores the company’s dedication to Enabling the Outcome™ for patients worldwide. By providing advanced supply chain and logistics solutions, Cryoport is poised to support the life sciences community in overcoming supply chain challenges and driving the next generation of medical breakthroughs.